Search clinical trials for: Risperidone 2 mg

Total 25202 results

Rovi Pharmaceuticals Laboratories

Completed

Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths (PRISMA-1)

Schizophrenia | Schizoaffective Disorder

Spain, South Africa, Russian Federation, Croatia
Janssen-Cilag S.p.A.

Completed

Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder
Rovi Pharmaceuticals Laboratories

Completed

Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia (PRISMA-3)

Acute Schizophrenia

United States, Ukraine
Rovi Pharmaceuticals Laboratories

Recruiting

Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia (QUARTZ)

Schizophrenia

Jordan
Pfizer

Completed

Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone

Psychotic Disorders | Schizophrenia

Russian Federation, Canada
Rovi Pharmaceuticals Laboratories

Completed

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension (PRISMA-3_OLE)

Schizophrenia

United States, Ukraine
CicloMed LLC
Cmed Clinical Services

Completed

Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Galderma R&D

Completed

Performance of Different Application Regimens of ACTINICA® on Protection From UVR-induced Erythema After One Day of Sun Exposure in Fair-skinned Healthy Subjects.

Healthy Subjects, Male or Female, of 18-60 Years Old, With Phototype I, II or III, Not Pre-treated/Pre-protected Skin

France
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Spain, United States, Italy, Taiwan, Thailand, Poland, Russian Federation, Israel, Ukraine, Mexico, Philippines, Georgia, United Kingdom, Chile, France, Bulgaria, Czechia, Greece, Hungary, Romania, Turkey, Germany, Puerto Rico, Japan
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy

Advanced Solid Tumor

United States
Kythera Biopharmaceuticals

Completed

Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

Healthy | Submental Fat

United States, Canada, Australia, United Kingdom
Proteimax Biotechnology Israel LTD

Recruiting

Effect of Consumption of Pep19 on Quality of Life

Quality of Life | Obesity | Sleep Quality

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study of Pevonedistat in Adult East Asian Participants

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Japan, Taiwan, Korea, Republic of
AstraZeneca

Completed

AZD5069 Neutrophil Function Study

Chemokine Receptor 2 (CXCR2) Antagonist

United Kingdom
Tunitas Therapeutics, Inc.
Tunitas Therapeutics Australia Pty Ltd

Terminated

Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects

Allergy and Immunology

Australia
Aaron R. Mangold

Completed

Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

Cutaneous Lichen Planus

United States
Centre for Addiction and Mental Health

Recruiting

Does Psilocybin Require Psychedelic Effects to Treat Depression? (PSI-RIS)

Treatment-resistant Depression

Canada
Janssen-Cilag International NV

Active, not recruiting

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings (CASPAR)

Schizophrenia

Rwanda
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

Schizophrenia

Rwanda
Eisai Inc.

Completed

Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects

Purpura, Thrombocytopenic, Idiopathic | Chronic Thrombocytopenia | Acute Idiopathic Thrombocytopenic Purpura

Netherlands
Medical College of Wisconsin

Completed

Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Relapsed Adult AML

United States
Novartis Pharmaceuticals

Completed

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Breast Cancer | Hematologic Neoplasms

Netherlands, Switzerland, United Kingdom, United States
Vantia Ltd

Completed

Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH) (EQUINOC)

Nocturia

United States
Eisai Inc.
Eisai Limited

Completed

An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

Diabetic Neuropathy

United States
Vanda Pharmaceuticals

Completed

Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)

Non-24-Hour-Sleep-Wake Disorder
Sunovion

Completed

Dasotraline SEP360-105 Pediatric PK/PD Study

Pediatric Attention Deficit Hyperactivity Disorder

United States
R-Pharm

Terminated

Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer (IXTEND)

Breast Neoplasms

United States
Zydus Therapeutics Inc.

Recruiting

Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis (EPICS-III)

Primary Biliary Cholangitis

United States, Argentina, Iceland, Turkey
Gannex Pharma Co., Ltd.
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
Zydus Therapeutics Inc.

Suspended

Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

Dyslipidemias

United States
Arena Pharmaceuticals

Completed

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis (ADVISE)

Atopic Dermatitis

United States, Australia, Canada
Hivih
Venn Life Sciences

Completed

Single Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of BDM-2 in Healthy Male Subjects.

Healthy

United Kingdom
Marion Trousselard

Terminated

Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety?

Anxiety State

France
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Eisai Inc.

Completed

Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States, France, United Kingdom, Germany, Spain, Belgium, Argentina, Israel, Poland, Romania, Korea, Republic of, Canada, Netherlands, Australia, New Zealand, Singapore, Brazil, Russian Federation, Austria, Thailand, Italy, ... and more
Pfizer

Completed

A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions

Healthy

Belgium
Gannex Pharma Co., Ltd.

Withdrawn

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH

Nonalcoholic Steatohepatitis (NASH)
NYU Langone Health

Active, not recruiting

Nivolumab Combined With BMS-986253 in HCC Patients

Hepatocellular Carcinoma

United States
Pfizer

Withdrawn

Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia

Dyslipidemia | Hypercholesterolemia
KLS Martin
Clinical Study Centers, LLC

Recruiting

Prospective Post-market Clinical Follow-up Study of the HBS 2 Resorb Mg in Patients With Intra- and Extraarticular Fractures, Pseudarthroses and Arthrodesis of Small Bones and Bone Fragments.

Arthrosis | Pseudarthrosis | Intraarticular Fracture | Extraarticular Fracture

Germany
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (APECS)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment | Prodromal Alzheimer's Disease
AstraZeneca

Active, not recruiting

A Study of CIN-107 in Adults With Primary Aldosteronism

Primary Aldosteronism | Hyperaldosteronism

United States
Rovi Pharmaceuticals Laboratories

Completed

Comparative Bioavailability of Risperidone

Schizophrenia

United States
AmtixBio Co., Ltd.
Novotech (Australia) Pty Limited

Completed

A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis

Onychomycosis

New Zealand
Kadmon Corporation, LLC
Quotient Sciences

Completed

A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability

Healthy Volunteers

United Kingdom
GlaxoSmithKline

Completed

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

Restless Legs Syndrome | Restless Legs Syndrome (RLS)

United States
Natrogen Therapeutics International, Inc

Unknown

Efficacy and Tolerability Study of Natura-Alpha in the Treatment of Patients With Active Ulcerative Colitis

Ulcerative Colitis

United States
Health Ever Bio-Tech Co., Ltd.

Completed

MCS in the Treatment of Lower Urinary Tract Symptoms (MCS_LUTS)

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

United States
RECORDATI GROUP

Completed

Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury

Neurogenic Detrusor Overactivity

Czechia, France, Poland, Portugal
Concert Pharmaceuticals

Completed

Open-Label Crossover Study Comparing CTP-543 to Jakafi®

Healthy

United States

Search clinical trials for: Risperidone 2 mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations